Abstract
In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device's success, or a combination therapy's clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.
| Original language | English (US) |
|---|---|
| Title of host publication | Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development |
| Publisher | Springer New York |
| Pages | 163-174 |
| Number of pages | 12 |
| ISBN (Electronic) | 9781493926817 |
| ISBN (Print) | 9781493926800 |
| DOIs | |
| State | Published - Jun 15 2015 |
Fingerprint
Keywords
- Gene expression
- Histology
- Immunohistochemistry
- Product development
- qPCR
- Quantitative histomorphometry
- Quantitative polymerase chain reaction
- RT-PCR
ASJC Scopus subject areas
- Medicine(all)
Cite this
Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development. / Audet, Robert G.; Diller, Robert B.; Kellar, Robert S.
Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Springer New York, 2015. p. 163-174.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development
AU - Audet, Robert G.
AU - Diller, Robert B.
AU - Kellar, Robert S
PY - 2015/6/15
Y1 - 2015/6/15
N2 - In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device's success, or a combination therapy's clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.
AB - In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device's success, or a combination therapy's clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.
KW - Gene expression
KW - Histology
KW - Immunohistochemistry
KW - Product development
KW - qPCR
KW - Quantitative histomorphometry
KW - Quantitative polymerase chain reaction
KW - RT-PCR
UR - http://www.scopus.com/inward/record.url?scp=85026217533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026217533&partnerID=8YFLogxK
U2 - 10.1007/7653_2014_38
DO - 10.1007/7653_2014_38
M3 - Chapter
AN - SCOPUS:85026217533
SN - 9781493926800
SP - 163
EP - 174
BT - Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development
PB - Springer New York
ER -